The Latest Breaking News from MRK

Raging inflation and the Fed’s commitment to bring it under control with rate hikes are raising recession worries. However, according to BofA, the market could see a rally later this year. Given the macro uncertainties, we think investors should add fundamentally solid stocks Microsoft (MSFT), Merck & Co. (MRK), and…

The rising prevalence of chronic diseases and the aging population are major growth drivers for the healthcare industry. In addition, increased investments in technological advancements should further bolster the industry’s growth. Thus, we think it may be prudent to buy quality healthcare stocks Pfizer Inc. (PFE), Merck & Co. (MRK),…

The Fed’s continued monetary policy tightening and consequent recession fears are expected to keep the stock market under pressure in the upcoming months. However, bullish traders could keep paying with fundamentally strong stocks The Coca-Cola Company (KO), AbbVie (ABBV), and Merck & Co. (MRK). Read more….

Persistent rate hikes by the Fed and rising odds of a recession have aggravated market turbulence and led investors to seek refuge in defensive sectors such as healthcare. Defensive stocks tend to perform well in declining markets due to the steady demand for their products. Hence, consistent dividend-yielding drug stocks…

Someone with a lot of money to spend has taken a bullish stance on Merck & Co (NYSE:MRK). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

A whale with a lot of money to spend has taken a noticeably bearish stance on Merck & Co. Looking at options history for Merck & Co (NYSE:MRK) we detected 17 strange trades.

Persistent economic turbulence and an uncertain outlook have led investors to prioritize steady income generation from their investments. Hence, fundamentally sound dividend yielders with a solid track record and potential for perpetual growth Merck (MRK), Abbott (ABT), Cigna (CI), Energy Transfer (ET), and Kronos (KRO) could be permanent additions to…

The stock market has rebounded lately from the decline in the year's first half, thanks to better-than-expected corporate earnings and the expectation of easing inflationary pressure. However, a still uncomfortable inflation level and the possible aggressive rate hikes could keep the market volatile. The Dogs of the Dow investment strategy…

  A whale with a lot of money to spend has taken a noticeably bearish stance on Merck & Co. Looking at options history for Merck & Co (NYSE:MRK) we detected 10 strange trades.

Even though the inflation declined slightly from the 40-year high in July, it stayed elevated. Therefore, the Fed could maintain its hawkish stance on tightening monetary policy, which will drive market volatility. Amid this fear-driven market, we think it could be prudent to invest in fundamentally sound stocks AbbVie (ABBV),…

The pharmaceutical industry is growing rapidly with advancements in drug manufacturing and a paradigm shift to personalized medicines. Moreover, despite soaring prices, supportive fiscal policies are expected to keep consumer demand stable. Quality pharmaceutical stocks Pfizer (PFE) and Merck (MRK) have outperformed the broader market over the past year and…